Celgene’s Otezla (Apremilast) receives Japanese regulatory approval
Posted on24 Dec 2016
TagsApremilast, Celgene, drug regulatory body in japan, Labor and Welfare, Ministry of Health, Plaque psoriasis, psoriasis
Comments0
Brand Name: Otezla Molecule: Apremilast Developed By: Celgene Corporation Apremilast (brand name Otezla) is a medication for the treatment of certain types... Read More
FDA approves Inflectra biosimilar for rheumatoid arthritis, psoriasis
The FDA has approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Infectra is a biosimilar to Remicade (infliximab), and can be prescribed... Read More